Ovarian Low Malignant Potential Tumor

An ovarian low malignant potential tumor—also called a borderline ovarian tumor—is a growth that starts from the surface lining (epithelium) of the ovary. It is not completely benign, because the cells look more active and crowded than normal under the microscope. But it is also not fully cancer, because the cells do not invade the surrounding tissue the way true cancer cells do. Because invasion is absent, these tumors usually grow slowly, are often found at an early stage, and most people do very well after surgery. Long-term survival is high, but careful follow-up is still needed because a small number can recur or, rarely, change into low-grade cancer over many years. Cancer.gov+1

An ovarian low malignant potential (LMP) tumor is an abnormal growth that starts in the ovary’s surface layer. Under the microscope it looks more “active” than a simple benign cyst, but it does not invade nearby tissue the way true cancer does. That is why doctors also call it a borderline ovarian tumor. Most people do very well after surgery, and many can keep fertility if the tumor is found early. Survival is excellent (often above 90–95% at 10 years), especially in early stages. The main treatment is surgery, not chemotherapy. Drug treatment may be considered only in selected advanced, recurrent, or hormone-sensitive cases, and evidence is limited. Canadian Cancer Society+3Cancer.gov+3PMC+3

Other names

• Borderline ovarian tumor (BOT)

• Tumor of low malignant potential (LMP)

• Atypical proliferative tumor (older wording; many modern pathology groups prefer “borderline” and note that the 2020 WHO system uses “borderline” across several histologic types). ICCR

Types

Borderline tumors come in several subtypes. Doctors identify the type by looking at the cells and patterns in the lab:

1. Serous borderline tumor (SBOT) – the most common; may have a “micropapillary” pattern and can be associated with tiny deposits (implants) on the peritoneum. PMC

2. Mucinous borderline tumor – often large, filled with mucus; two patterns are described (intestinal-type and endocervical-type). ScienceDirect

3. Seromucinous borderline tumor (recognized in the 2020 WHO scheme). ICCR

4. Endometrioid borderline tumor (rare). ScienceDirect

5. Clear cell borderline tumor (rare). ScienceDirect

6. Borderline Brenner (transitional) tumor (rare). ICCR

Pathologists also note special features that affect care, such as non-invasive vs invasive peritoneal implants in serous tumors, because that distinction guides follow-up and treatment. esgo.org

---

Causes and Risk Factors

We do not know one single cause. Instead, several risk factors slightly raise or lower the chance of a borderline tumor. Think of these as “tilting the odds,” not guarantees.

1. Age in young–mid adulthood – BOTs tend to appear a decade earlier than typical ovarian cancers. PMC

2. Number of lifetime ovulations – more ovulations over many years may slightly raise risk (similar to patterns in epithelial ovarian tumors). NCBI

3. No pregnancies (nulliparity) – fewer or no pregnancies often means more ovulations; risk may be a bit higher. NCBI

4. Early first period or late menopause – extends ovulation years. NCBI

5. Endometriosis – linked to some borderline types (especially endometrioid/clear cell patterns). ScienceDirect

6. Family history of epithelial ovarian tumors – overall link is weaker than for high-grade cancers but still relevant in family discussions. NCBI

7. Genetic changes in the tumor itself – common acquired mutations include KRAS and BRAF (especially in serous and mucinous borderline tumors). These are tumor findings, not inherited in most people. PMC

8. Infertility – sometimes overlaps with other risk factors; research shows mixed results. Medscape

9. Ovulation-induction medications – data are mixed; any increase in risk, if present, appears small and must be weighed against the benefit of pregnancy. Medscape

10. Smoking – more clearly linked to mucinous ovarian tumors (including borderline mucinous types). ScienceDirect

11. Obesity – may contribute via hormonal pathways shared with other epithelial ovarian tumors. NCBI

12. Hormone factors (estrogen/progesterone balance) – long, uninterrupted cycles can tilt risk. NCBI

13. Protective: combined oral contraceptive pills – lower the risk of many epithelial ovarian tumors over time; likely helps here too. NCBI

14. Protective: tubal ligation – lowers risk for epithelial ovarian tumors in general; mechanism likely reduces upward spread from pelvis. NCBI

15. Protective: breastfeeding – fewer ovulations during months of lactation. NCBI

16. Pelvic inflammatory processes – chronic pelvic inflammation may play a role in some individuals. NCBI

17. Prior benign mucinous or serous cystadenoma – some borderline tumors arise in a background of benign epithelial cysts. NCBI

18. Ovarian/endometrial “Müllerian” conditions – shared tissue origins may explain overlaps like seromucinous patterns. ICCR

19. Environmental exposures – studied broadly in ovarian tumors; firm links specific to BOTs are limited. NCBI

20. Personal history of certain low-grade ovarian tumors – rare patients can have both borderline and low-grade invasive tumors over time, tying them on a disease spectrum. PMC

---

Common Symptoms

Many people have no symptoms at first. When symptoms happen, they are often vague and come from a growing pelvic mass:

1. Lower abdominal or pelvic pain—dull, on one side or both.

2. Bloating or a feeling of fullness—clothes feel tighter.

3. Increase in abdominal size—from the mass or fluid.

4. Early fullness while eating—“I get full quickly.”

5. Frequent urination or urgency—mass presses on the bladder.

6. Constipation or bowel changes—pressure on the bowel.

7. Irregular periods or spotting (less common but possible).

8. Pain during sex—deep pelvic discomfort.

9. Back pain—referred from pelvic pressure.

10. Fatigue—non-specific, often from symptoms worsening slowly.

11. Unintended weight change—up or down.

12. Nausea/indigestion—from pressure and slowed gut movement.

13. A palpable pelvic/abdominal lump—found by the patient or clinician.

14. Sudden sharp pain from ovarian torsion—if the ovary twists (an emergency).

15. Shortness of breath—rare; could be due to fluid if disease spreads (much less common in borderline tumors). Cancer.gov

---

Diagnostic Tests

A. Physical Examination (what the clinician checks)

1. General exam and vital signs
   Your clinician checks weight, general health, and vitals (heart rate, blood pressure, temperature). This does not diagnose the tumor, but it sets the baseline and looks for signs of anemia, infection, or fluid. NCBI

2. Abdominal exam
   They feel for tenderness, a mass, or fluid in the belly (ascites). Most borderline tumors do not cause large fluid collections, but a very enlarged ovary can be felt. Cancer.gov

3. Visual pelvic inspection
   During a speculum exam, the cervix and vagina are checked for other issues (polyps, bleeding sources). This does not diagnose an ovarian tumor but rules out other causes of symptoms. NCBI

B. Manual Tests (hands-on gynecologic assessment)

4. Bimanual pelvic exam
   The doctor gently feels the uterus and ovaries with one hand inside the vagina and one on the abdomen. A mobile, smooth mass suggests a cyst; fixed or complex masses raise concern and lead to imaging. NCBI

5. Rectovaginal exam
   This can better assess the space behind the uterus and detect nodules in the cul-de-sac (pouch of Douglas). Nodularity would prompt careful imaging and, if surgery occurs, targeted sampling. NCBI

6. Pain and mobility testing of the mass
   Gentle movement of the mass helps estimate whether it is attached to other organs. Borderline tumors are often non-invasive, so they are commonly mobile at early stages. Cancer.gov

C. Laboratory and Pathology Tests

7. CA-125 blood test
   CA-125 can be normal or mildly elevated in borderline tumors. A high value does not prove cancer; it simply guides risk assessment with ultrasound findings and age. Cancer.gov

8. HE4 and the ROMA score
   HE4 plus CA-125 can estimate the chance a mass is malignant in postmenopausal people; results are an aid, not a diagnosis. These tools help triage to a gynecologic oncologist when risk seems higher. Medscape

9. CEA and/or CA 19-9 (especially if the ultrasound suggests a mucinous tumor)
   These markers can be raised in mucinous ovarian tumors and also in gastrointestinal conditions, so they must be interpreted cautiously. ScienceDirect

10. Pregnancy test (β-hCG) and other tumor markers for the differential
    In younger patients, clinicians also check markers for germ-cell tumors (AFP, LDH, β-hCG) so they do not miss a different, potentially urgent diagnosis. MDPI

11. Complete blood count and metabolic panel
    These look for anemia, infection, or organ issues and help plan surgery safely. NCBI

12. Frozen section (during surgery)
    A pathologist examines a small piece of the mass while you are in the operating room to guide the extent of surgery (for example, fertility-sparing vs. more extensive staging). The final, permanent report may add details that change the name or stage. Cancer.gov

13. Final histopathology (gold standard)
    On the permanent slides, the pathologist confirms a borderline pattern—epithelial proliferation without stromal invasion—and writes the subtype (serous, mucinous, etc.). This report is what ultimately makes the diagnosis. ICCR

14. Immunohistochemistry (IHC)
    Markers like WT1, PAX8, CK7, ER (and others) help confirm that the tumor is of Müllerian/ovarian origin and support the subtype. IHC refines borderline vs. other look-alikes. ICCR

15. Molecular testing (KRAS, BRAF, others)
    Many serous and mucinous borderline tumors carry KRAS or BRAF mutations. This can support the diagnosis and, in research settings, helps explain the biology linking borderline tumors with some low-grade carcinomas. PMC

D. Electrodiagnostic Tests (important note)

16. Electrodiagnostic tests (EEG/EMG/nerve conduction) are not used to diagnose ovarian borderline tumors
    These tests check brain, nerve, or muscle function and do not play a role in diagnosing ovarian masses. If you see them ordered, it is for other medical reasons, not for the ovarian tumor itself. Pre-surgery, some people get an ECG (electrocardiogram) to check heart safety for anesthesia, but that does not evaluate the tumor. NCBI

E. Imaging Tests (key to triage and planning)

17. Transvaginal ultrasound (first-line test)
    This is the main test for an adnexal mass. Experts use structured systems (like the IOTA Simple Rules) to sort a mass into likely benign, likely malignant, or uncertain. Borderline tumors often look complex (multi-locular, septations, papillary projections). PMC+2Radiopaedia+2

18. Doppler ultrasound
    Looks at blood flow in solid areas or papillary projections. It supports the overall impression but cannot by itself prove cancer vs. borderline. PMC

19. MRI of the pelvis (with contrast)
    Helpful when ultrasound is indeterminate—MRI shows the internal architecture, mural nodules, and hemorrhage or fat. It improves confidence before planning surgery, especially for fertility-sparing approaches. ESMO

20. CT scan of abdomen/pelvis (and sometimes chest)
    CT is not needed for every small, clearly benign-appearing mass. It is used when the tumor is large/complex or when staging is required (e.g., suspected implants or spread). Rarely, PET-CT is used in selected problems, but it is not routine for borderline tumors. Cancer.gov

Non-Pharmacological Treatments (Therapies & Others)

1. Active Surveillance after Definitive Surgery
   What it is: Regular follow-up visits, pelvic exams, ultrasound/CT as needed, and CA-125 (if elevated before) rather than any immediate additional therapy.
   Purpose: Catch rare recurrences early while avoiding unnecessary treatment.
   Mechanism: Monitoring works because most LMP tumors behave indolently; surgery removes visible disease, and careful checks detect the uncommon relapse in time for re-operation. Cancer.gov

2. Fertility-Sparing Surgery (Cystectomy or Unilateral Salpingo-Oophorectomy)
   What it is: Removing only the cyst or the affected ovary and tube, keeping the uterus and the other ovary.
   Purpose: Preserve fertility while treating the tumor safely in early stages.
   Mechanism: Borderline tumors lack destructive invasion; removing the visible tumor with proper staging usually controls disease while leaving reproductive organs intact. NCCN+1

3. Standard Surgical Staging (Peritoneal Washings, Omentectomy, Peritoneal Biopsies)
   What it is: Careful inspection and sampling inside the abdomen to check spread.
   Purpose: Correct staging guides prognosis and the need for more treatment.
   Mechanism: Staging maps microscopic implants, which drive risk and follow-up intensity. Cancer.gov

4. Completion Surgery After Childbearing (Selected Cases)
   What it is: Removing the remaining ovary ± uterus after finishing having children.
   Purpose: Reduce small risk of later recurrence when prior surgery was fertility-sparing.
   Mechanism: Eliminates residual epithelial ovarian tissue that could form new borderline growths; recommendations vary across guidelines. PubMed

5. Minimally Invasive Surgery (Laparoscopy) When Appropriate
   What it is: Keyhole surgery by trained gynecologic oncologists.
   Purpose: Faster recovery and fewer complications in suitable patients.
   Mechanism: Same oncologic principles; smaller incisions with careful specimen handling to avoid cyst rupture. PMC

6. Re-operation for Recurrence
   What it is: Surgery again if a new borderline lesion appears.
   Purpose: Remove recurrent disease and reassess stage; chemotherapy is rarely needed.
   Mechanism: Most recurrences remain borderline and are still best managed surgically. Cancer.gov

7. Specialized Pathology Review
   What it is: Slides reviewed by a gynecologic pathologist.
   Purpose: Confirm “borderline” vs. invasive cancer vs. benign—misclassification affects treatment.
   Mechanism: Expert reading reduces false up- or down-grading. annalsofoncology.org

8. Preconception Counseling
   What it is: Visit to plan pregnancy after fertility-sparing treatment.
   Purpose: Time pregnancy safely and plan follow-up while pregnant.
   Mechanism: Aligns surveillance with obstetric care and clarifies timing for any completion surgery later. NCCN

9. Pelvic Floor & Core Rehabilitation (Post-Surgery Recovery)
   What it is: Guided exercises and physiotherapy.
   Purpose: Reduce pain, improve pelvic strength, and support sexual function after pelvic surgery.
   Mechanism: Restores muscle tone and mobility, improving quality of life during long survivorship. Canadian Cancer Society

10. Nutrition Counseling (Weight, Fiber, Balanced Diet)
    What it is: Individualized healthy-diet plan.
    Purpose: Support recovery, energy, and overall health; no diet cures LMP tumors.
    Mechanism: Adequate protein and micronutrients aid wound healing and resilience during surveillance. Canadian Cancer Society

11. Smoking Cessation
    What it is: Structured program to stop smoking.
    Purpose: Improve surgical outcomes, reduce complications and general cancer risks.
    Mechanism: Better oxygenation, immune function, and wound healing. Canadian Cancer Society

12. Vaccinations (Per Routine Care)
    What it is: Staying current with standard vaccines (e.g., influenza, COVID-19 as advised).
    Purpose: Prevent infections that could complicate recovery.
    Mechanism: Induces protective immunity; not tumor-specific. Canadian Cancer Society

13. Psychosocial Support / Counseling
    What it is: Counseling or support groups.
    Purpose: Reduce anxiety about recurrence; improve coping and adherence to follow-up.
    Mechanism: Evidence from oncology survivorship shows mental-health support improves quality of life. Canadian Cancer Society

14. Sexual Health Counseling
    What it is: Guidance on dyspareunia, lubrication, and timing after surgery.
    Purpose: Restore comfortable intimacy and address fear.
    Mechanism: Education + pelvic floor work + local measures as appropriate. Canadian Cancer Society

15. Genetic Risk Review (Personal/Family History-Based)
    What it is: Evaluate family history; consider genetics referral if concerning features.
    Purpose: Identify hereditary risk (rare for borderline tumors, but prudent to check context).
    Mechanism: Targeted testing when criteria met guides long-term prevention in families. annalsofoncology.org

16. Bone Health & Exercise Plan
    What it is: Weight-bearing exercise and vitamin D assessment as part of survivorship.
    Purpose: Maintain strength and reduce fracture risk; especially relevant if later hormonal therapy is considered.
    Mechanism: Exercise builds bone/muscle; vitamin D supports mineralization. Canadian Cancer Society

17. Iron and Anemia Check (If Heavy Menses or Perioperative Loss)
    What it is: Screen and treat iron deficiency when indicated.
    Purpose: Improve energy and recovery.
    Mechanism: Restores red cell mass and oxygen transport. Canadian Cancer Society

18. Careful Pregnancy Planning After Surgery
    What it is: Coordinate with OB-GYN and oncologist.
    Purpose: Safe timing and monitoring during pregnancy.
    Mechanism: Aligns ultrasound surveillance with prenatal care; LMP tumors rarely threaten pregnancy once treated. NCCN

19. Menopause Symptom Counseling (If Both Ovaries Removed)
    What it is: Discuss non-hormonal strategies first; individualized decisions about HRT require oncology input.
    Purpose: Manage hot flashes, sleep, mood.
    Mechanism: Lifestyle, CBT, and selected non-hormonal options can help; HRT decisions are case-by-case. esgo.org

20. Long-Term Survivorship Plan
    What it is: Written plan for tests, schedule, and who to call.
    Purpose: Clear roadmap reduces missed visits and anxiety.
    Mechanism: Standardized intervals (e.g., exam/ultrasound) reflect excellent long-term prognosis and rare but possible late events. Cancer.gov

---

Drug Treatments

Key evidence note: For typical early-stage LMP tumors, drug therapy is not standard; surgery is the primary treatment. In selected advanced, recurrent, or hormone-sensitive cases—especially with low-grade serous behavior—clinicians may consider endocrine therapy (off-label) or, rarely, chemotherapy similar to epithelial ovarian cancer regimens. No drug is FDA-approved specifically for “borderline ovarian tumor.” Decisions are individualized and evidence is limited. Cancer.gov+2Cancer.gov+2

Below are drugs sometimes used in related ovarian settings with FDA labels referenced (breast/ovarian indications) to show mechanisms, dosing frameworks, and safety—not endorsements for routine LMP use. Always treat off-label care in a specialist center.

1. Letrozole (Femara)
   Class: Aromatase inhibitor (AI).
   Usual dose/time (per label for breast cancer): 2.5 mg orally once daily; duration in oncology varies by indication.
   Purpose in this context: Sometimes used off-label for recurrent, hormone-receptor–positive borderline/low-grade serous disease to slow estrogen-driven growth.
   Mechanism: Blocks aromatase, lowering estrogen levels that may fuel ER-positive tumors.
   Side effects: Arthralgia, hot flashes, fatigue; rare bone loss with long use—monitor bone health. (FDA labeling cited for pharmacology/dosing/safety.) FDA Access Data+1

2. Anastrozole (Arimidex)
   Class: Aromatase inhibitor.
   Dose/time (label for breast cancer): 1 mg orally once daily.
   Purpose: Off-label alternative AI in ER-positive recurrent borderline/low-grade serous settings.
   Mechanism: Lowers estrogen synthesis; may slow hormone-dependent cell proliferation.
   Side effects: Hot flashes, arthralgia, bone density loss—plan bone health support. FDA Access Data

3. Tamoxifen (Nolvadex/Soltamox)
   Class: Selective estrogen receptor modulator (SERM).
   Dose/time (labels in breast/DCIS): Commonly 20 mg daily.
   Purpose: Off-label endocrine option if AI not tolerated.
   Mechanism: Competes with estrogen at ER; can slow ER-dependent tumor cell growth.
   Side effects: Hot flashes, thromboembolism risk; strict contraception needed due to fetal risk. FDA Access Data+1

4. Leuprolide (Lupron/Lupron Depot)
   Class: GnRH agonist.
   Dose/time (label examples): Various depot doses every 1–3 months depending on indication.
   Purpose: Off-label ovarian suppression to lower estrogen in hormone-sensitive disease.
   Mechanism: After brief stimulation, down-regulates pituitary GnRH receptors → suppresses ovarian steroidogenesis.
   Side effects: Menopausal symptoms, bone loss with prolonged use—combine with bone protection plan. FDA Access Data+1

5. Goserelin (Zoladex)
   Class: GnRH agonist (implant).
   Dose/time (label examples): 3.6 mg SC every 28 days (regimen varies by indication).
   Purpose: Off-label ovarian suppression similar to leuprolide.
   Mechanism: Sustained GnRH stimulation → pituitary desensitization → low estrogen.
   Side effects: Hot flashes, mood change, bone density loss with long-term use. FDA Access Data+1

6. Paclitaxel (Taxol)
   Class: Taxane chemotherapy.
   Dose/time (ovarian cancer labels): Commonly 135–175 mg/m² IV every 3 weeks when used with platinum (per ovarian carcinoma trials).
   Purpose: Not routine for LMP; reserved for rare invasive evolution or mixed low-grade serous contexts after specialist discussion.
   Mechanism: Stabilizes microtubules → halts mitosis → cell death.
   Side effects: Neutropenia, neuropathy, alopecia; requires premedication and monitoring. FDA Access Data+2FDA Access Data+2

7. Carboplatin (Paraplatin)
   Class: Platinum chemotherapy.
   Dose/time (ovarian label): Dosed by AUC (e.g., AUC 5–6) IV every 3 weeks, often with paclitaxel.
   Purpose: Same caution as above—generally not for classic LMP unless invasive behavior.
   Mechanism: DNA crosslinking → apoptosis.
   Side effects: Myelosuppression, nausea, neuropathy risk. FDA Access Data+2FDA Access Data+2

8. Bevacizumab (Avastin)
   Class: Anti-VEGF monoclonal antibody.
   Dose/time (ovarian cancer labels): 15 mg/kg IV q3w with chemo then maintenance in certain recurrent epithelial ovarian settings.
   Purpose: Rare, selected use when the clinical picture behaves like epithelial ovarian cancer; not standard for borderline disease.
   Mechanism: Blocks VEGF → anti-angiogenic effect → starves tumors of blood supply.
   Side effects: Hypertension, proteinuria, bleeding/perforation risk—careful selection needed. FDA Access Data

9. Ondansetron (example antiemetic)
   Class: 5-HT3 antagonist.
   Purpose/Mechanism: Blocks serotonin receptors in the gut/brain to prevent nausea if chemotherapy is used for non-standard indications; also helpful after surgery.
   Safety: Headache, constipation; generally well tolerated. (Use per institutional guidelines.) esgo.org

10. Granulocyte Colony-Stimulating Factor (G-CSF) (e.g., filgrastim/pegfilgrastim)
    Class: Hematopoietic growth factor.
    Purpose/Mechanism: In chemo contexts, reduces neutropenia by stimulating marrow granulocyte production; not needed for typical LMP care.
    Safety: Bone pain, rare splenic issues; used per chemo risk category. esgo.org

11. Analgesics (e.g., acetaminophen/NSAIDs as appropriate)
    Purpose/Mechanism: Symptom relief after surgery; reduce prostaglandin-mediated pain (NSAIDs).
    Safety: Monitor renal/GI risks with NSAIDs; follow perioperative protocols. esgo.org

12. Anticoagulation (perioperative, risk-based)
    Purpose/Mechanism: Prevents clots after pelvic surgery via pharmacologic prophylaxis when indicated.
    Safety: Bleeding risk balanced against clot risk per guidelines. esgo.org

Important disclaimer: The anti-cancer drugs above are not routinely indicated for classic borderline tumors after complete surgery. Use outside those narrow contexts is off-label and specialist-dependent. Always follow local protocols and discuss risks/benefits. Cancer.gov+1

---

Dietary Molecular Supplements

1. Vitamin D3
   Dose (general wellness range): Often 800–2000 IU/day (individualize per labs).
   Function/Mechanism: Supports bone health, which matters if future ovarian suppression is used; modulates immune function. Not a tumor treatment. esgo.org

2. Calcium (from food first; supplement if needed)
   Dose: Typical 1000–1200 mg/day total intake from diet ± supplements.
   Function: Bone mineralization support if on long-term endocrine suppression; prevents deficiency. esgo.org

3. Protein (whey/soy-free if advised)
   Dose: ~1.0–1.2 g/kg/day during recovery unless contraindicated.
   Function: Tissue repair post-surgery; supports immune proteins; not disease-specific. Canadian Cancer Society

4. Omega-3 (EPA/DHA)
   Dose: Common 1–2 g/day combined EPA/DHA (check bleeding risk).
   Function: Anti-inflammatory effects may help general recovery and wellbeing. Canadian Cancer Society

5. Iron (only if deficient)
   Dose: Guided by ferritin/hemoglobin; avoid routine use without labs.
   Function: Restores red cells after perioperative loss; improves fatigue when deficient. Canadian Cancer Society

6. Vitamin B12/Folate (if deficient)
   Dose: As per deficiency correction protocols.
   Function: Supports red cell production and neurologic function; check levels first. Canadian Cancer Society

7. Probiotics (evidence mixed)
   Dose: Per product; short courses after antibiotics may help gut comfort.
   Function: Gut microbiome support during recovery; not tumor-directed. Canadian Cancer Society

8. Magnesium
   Dose: 200–400 mg/day elemental (adjust for kidney function).
   Function: Muscle/nerve function; may help constipation/cramps post-op. Canadian Cancer Society

9. Zinc (short term if low)
   Dose: 8–15 mg/day elemental for limited duration.
   Function: Wound healing and immune enzyme function; avoid excessive dosing. Canadian Cancer Society

10. Multivitamin (basic)
    Dose: Once daily standard formulation.
    Function: Safety net for micronutrient gaps; no anti-tumor effect. Canadian Cancer Society

---

Immunity-Booster / Regenerative / Stem-Cell Drugs

There are no approved “immunity-booster,” regenerative, or stem-cell drugs to treat ovarian LMP tumors. Stem-cell therapies are not standard and should not be used outside a formal clinical trial. If anyone offers you such products for LMP, seek a second opinion from a gynecologic oncologist. Support your immune system through vaccines, sleep, nutrition, movement, and stress care—not unproven drugs. Cancer.gov+1

(To align with your requested format, here are six safe, evidence-aligned medical strategies—not “stem cell drugs”—that clinicians actually use to protect health when appropriate. Each is standard care in the right context, not tumor therapy):

1. Seasonal Influenza Vaccine — lowers risk of flu complications during recovery; works by inducing specific antibodies. esgo.org

2. COVID-19 Vaccination/Boosters (per guidance) — reduces severe infection risk; induces adaptive immunity. esgo.org

3. Pneumococcal Vaccine (risk-based) — prevents serious bacterial pneumonia in eligible adults; stimulates polysaccharide/protein-conjugate immunity. esgo.org

4. Bone-Protective Measures if on Long-Term Endocrine Suppression — calcium/vitamin D, weight-bearing exercise; mechanism: supports bone remodeling balance. esgo.org

5. Thrombosis Prophylaxis After Pelvic Surgery (risk-based) — prevents postoperative clots by inhibiting coagulation pathways. esgo.org

6. Evidence-Based Sleep & Stress Programs — improves immune resilience via neuroendocrine pathways; supports quality of life in survivorship. Canadian Cancer Society

---

Surgeries

1. Ovarian Cystectomy
   Procedure: Removes only the cyst with a rim of normal tissue.
   Why: Preserve the ovary in select early LMP when fertility is a priority. NCCN

2. Unilateral Salpingo-Oophorectomy (USO)
   Procedure: Removes the affected ovary and tube.
   Why: Standard fertility-sparing operation when disease is confined to one side. Cancer.gov

3. Bilateral Salpingo-Oophorectomy (BSO) ± Hysterectomy
   Procedure: Removes both ovaries/tubes with or without the uterus.
   Why: For those not seeking fertility or when disease is bilateral; reduces recurrence risk. Cancer.gov

4. Surgical Staging Components
   Procedure: Peritoneal washings, omentectomy, peritoneal biopsies; removal of visible implants.
   Why: Accurate stage drives prognosis and follow-up. Cancer.gov

5. Debulking/Cytoreductive Surgery (Advanced Disease)
   Procedure: Remove as much tumor as safely possible when spread exists.
   Why: Improves outcomes and lowers tumor burden even in advanced borderline disease. Cancer.gov

---

Preventions

No lifestyle step guarantees prevention, but these help your overall health and surgical recovery.

1. Don’t ignore persistent bloating/pelvic swelling—seek evaluation early. Cancer.gov

2. Avoid smoking; enroll in cessation support. Canadian Cancer Society

3. Maintain healthy body weight and regular activity. Canadian Cancer Society

4. Use contraception thoughtfully; long-term OCPs reduce invasive ovarian cancer risk (data in cancer risk; specific LMP data limited). esgo.org

5. Know family history; request genetics referral if red flags exist. annalsofoncology.org

6. Routine gynecologic care and prompt assessment of new symptoms. NCCN

7. Balanced diet rich in fruits/vegetables and adequate protein. Canadian Cancer Society

8. Plan pregnancies with your care team after fertility-sparing surgery. NCCN

9. Keep vaccines current to avoid post-op infections. esgo.org

10. Follow your survivorship plan and never skip follow-up visits. Cancer.gov

---

When to See a Doctor

• New or persistent bloating, pelvic pressure, or feeling “full” quickly.

• New pelvic pain or a rapidly growing abdominal mass.

• Abnormal periods after surgery, unexpected bleeding, or new severe cramps.

• Unexplained weight change or fatigue.

• Any new symptoms during pregnancy after fertility-sparing surgery.

• Fever, redness, or wound issues after surgery. Cancer.gov+1

---

What to Eat and What to Avoid

1. Eat: colorful vegetables and fruits daily for fiber and micronutrients. Avoid: ultra-processed snacks high in added sugar. Canadian Cancer Society

2. Eat: lean proteins (fish, eggs, legumes, poultry) for recovery. Avoid: frequent deep-fried foods. Canadian Cancer Society

3. Eat: whole grains (oats, brown rice). Avoid: excess refined carbs if they crowd out fiber. Canadian Cancer Society

4. Eat: healthy fats (olive oil, nuts). Avoid: trans fats. Canadian Cancer Society

5. Drink: water; keep hydrated. Avoid: heavy alcohol—no health benefit here for LMP. Canadian Cancer Society

6. Consider: calcium + vitamin D from food; supplement if advised. Avoid: high-dose supplements without a need. esgo.org

7. Aim: steady protein at each meal for healing. Avoid: crash diets in recovery. Canadian Cancer Society

8. Add: fiber gradually to avoid constipation post-op. Avoid: very low-fiber patterns. Canadian Cancer Society

9. Limit: excess salt to reduce bloating. Avoid: daily salty packaged foods. Canadian Cancer Society

10. Enjoy: culturally familiar, balanced meals that you can sustain long term. Avoid: “miracle cancer diets”—there’s no evidence they treat LMP. Canadian Cancer Society

---

Frequently Asked Questions (FAQ)

1. Is an LMP tumor cancer?
   It is borderline—more than benign, less than invasive cancer, and outcomes are excellent with proper surgery. Cancer.gov

2. What is the main treatment?
   Surgery with correct staging; most early cases need no chemo. Cancer.gov

3. Can I keep my fertility?
   Often yes. Many people have fertility-sparing surgery if disease is early and confined. NCCN

4. Will I need chemotherapy?
   Usually no for typical early disease. Rarely considered for advanced, recurrent, or invasive features. Cancer.gov

5. Are hormone pills used?
   Sometimes, off-label (like aromatase inhibitors or tamoxifen) in hormone-sensitive recurrences; evidence is limited. Cancer.gov

6. What is the chance of living a long life?
   Very high—10-year survival around or above 90–95% overall, stage-dependent. Cancer.gov+1

7. How often do I follow up?
   Your team sets a schedule of exams and imaging as needed, especially in the first years. Cancer.gov

8. Can borderline tumors come back?
   Yes, but recurrences are often still borderline and treatable with surgery. Cancer.gov

9. Should I have completion surgery later?
   Sometimes after childbearing; guidance varies across societies—discuss personally. PubMed

10. Is genetic testing needed?
    Usually not, but discuss if family history is strong for ovarian/breast cancers. annalsofoncology.org

11. Does diet cure it?
    No. Diet supports recovery but does not treat tumors. Canadian Cancer Society

12. Can I get pregnant after surgery?
    Many can, with coordinated care and timing; ask for preconception counseling. NCCN

13. Are “immunity boosters” or stem-cell shots helpful?
    No approved role in LMP; avoid non-evidence products. Cancer.gov

14. What warning signs should I watch?
    New bloating, pelvic pain/pressure, or fast-growing mass—see your doctor. Cancer.gov

15. Who should manage my care?
    A gynecologic oncologist with experience in borderline tumors. Cancer.gov

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 30, 2025.